Bernard H. Bochner

Bernard H. Bochner

Auto-generated profile, based on publicly available information

Bernard H. Bochner

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AZAhmet Zehir
Ahmet Zehir
RBRyma Benayed
Ryma Benayed
Ronak ShahRonak Shah
Ronak Shah
ASAijazuddin Syed
Aijazuddin Syed
SMSumit Middha
Sumit Middha
MBMichael F Berger
Michael F Berger
MSK-IMPACT is a clinical sequencing platform able to detect genomic mutations, copy number alterations and structural variants in a panel of cancer-related genes. This assay is implemented prospectively to inform patient enrollment in genomically matched clinical trials at Memorial Sloan Kettering Cancer Center (MSKCC). Sequencing results of tumor and matched normal tissue from a cohort of >10,000 patients with detailed clinical annotation provide an overview of the genomic landscape of advanced solid cancers and bring new insights into molecularly guided cancer therapy. Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible.

1 January 2009 in European Urology
Verified
Journal Article
Closed access
ASAhmad Shabsigh
Ahmad Shabsigh
RKRuslan Korets
Ruslan Korets
KVKinjal C. Vora
Kinjal C. Vora
CBChristine M. Brooks
Christine M. Brooks
ACAngel M. Cronin
Angel M. Cronin
SDS. Machele Donat
S. Machele Donat

4 February 2014 in Nature Reviews Urology
Verified
Journal Article
Closed access
GRGil Redelman-Sidi
Gil Redelman-Sidi
MGMichael S. Glickman
Michael S. Glickman
BBBernard H. Bochner
Bernard H. Bochner

30 September 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EAEliezer M. Van Allen
Eliezer M. Van Allen
KMKent W. Mouw
Kent W. Mouw
PKPhilip Kim
Philip Kim
GIGopa Iyer
Gopa Iyer
NWNikhil Wagle
Nikhil Wagle
JRJonathan E. Rosenberg
Jonathan E. Rosenberg
Cisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely understood. We performed whole-exome sequencing on pretreatment tumor and germline DNA from 50 patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy (25 pT0/pTis “responders,” 25 pT2+ “nonresponders”) to identify somatic mutations that occurred preferentially in responders. ERCC2, a nucleotide excision repair gene, was the only significantly mutated gene enriched in the cisplatin responders compared with nonresponders (q < 0.01). Expression of representative ERCC2 mutants in an ERCC2-deficient cell line failed to rescue cisplatin and UV sensitivity compared with wild-type ERCC2. The lack of normal ERCC2 function may contribute to cisplatin sensitivity in urothelial cancer, and somatic ERCC2 mutation status may inform cisplatin-containing regimen usage in muscle-invasive urothelial carcinoma. Significance: Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisplatin sensitivity in vitro. Nucleotide excision repair pathway defects may drive exceptional response to conventional chemotherapy. Cancer Discov; 4(10); 1140–53. ©2014 AACR. See related commentary by Turchi et al., p. 1118 This article is highlighted in the In This Issue feature, p. 1103

1 June 2015 in European Urology
Verified
Journal Article
Closed access
BBBernard H. Bochner
Bernard H. Bochner
GDGuido Dalbagni
Guido Dalbagni
DSDaniel D. Sjoberg
Daniel D. Sjoberg
JSJonathan Silberstein
Jonathan Silberstein
GPGal E. Keren Paz
Gal E. Keren Paz
VLVincent P. Laudone
Vincent P. Laudone

1 March 2002 in Journal of Urology
Verified
Journal Article
Closed access
HHHarry W. Herr
Harry W. Herr
BBBernard H. Bochner
Bernard H. Bochner
GDGuido Dalbagni
Guido Dalbagni
SDS. Machele Donat
S. Machele Donat
VRVictor E. Reuter
Victor E. Reuter
DBDean F. Bajorin
Dean F. Bajorin